REG - GENinCode PLC - Indiana University Medical School collaboration

GenincodeAnnouncement

23/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220323:nRSW6560Fa&default-theme=true

RNS Number : 6560F  GENinCode PLC  23 March 2022

 

GENinCode Plc

("GENinCode" or the "Company")

 

Collaboration with Indiana University School of Medicine

Study for testing Cardio inCode-SCORE for the risk of onset of cardiovascular
disease

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces its collaboration with
the Indiana University School of Medicine ("IU"). IU is the largest medical
school in the US and will undertake a 'Proof of Concept' study using Cardio
inCode-SCORE for the risk assessment of patients for onset of atherosclerotic
cardiovascular disease ("ASCVD"). ASCVD accounts for over 85% of all
cardiovascular disease deaths and is the leading cause of morbidity and
mortality in the US and globally.

 

According to the Centres for Disease Control and Prevention ("CDC"),
cardiovascular disease ("CVD") is the number one cause of death in the United
States and the decades‐long trend towards lower cardiovascular mortality
rates has begun to reverse, with an increase in total mortality during recent
years: https://www.cdc.gov/heartdisease/facts.htm
(https://www.cdc.gov/heartdisease/facts.htm) .

 

CVD disproportionately affects people of lower socioeconomic status, and those
of non‐white ethnicity. Early identification of subclinical disease in the
population can lead to better primary prevention of heart attack and stroke.
Current American College of Cardiology ("ACC") guidelines call for risk
stratification using validated instruments, such as the US National Heart Lung
and Blood Institute ("NHLBI") pooled risk cohort equation, drawing on clinical
parameters readily available such as blood pressure and cholesterol levels. In
addition, the guidelines endorse the use of "risk enhancing factors" such as
the Coronary Artery Calcium ("CAC") score, undertaken using computerised
tomography ("CT") imaging of the coronary arteries.

 

Whilst acknowledging family history as a risk factor, current guidelines have
not yet incorporated the potential of genetic risk assessment in the
prediction of ASCVD. Cardio inCode-SCORE provides an opportunity to apply
advanced polygenic testing to improve patient risk assessment and prognosis,
in a widely available form and at reduced cost compared with other test
modalities.

 

The primary aim of the IU study is to evaluate the association between the
Cardio inCode-SCORE genetic risk score ("GRS") and the presence of subclinical
coronary atherosclerosis evaluated by CAC.

CVD is a broad disease classification which encompasses conditions such as
coronary artery disease (causing angina, heart attacks, heart failure),
cerebrovascular disease (causing stroke, and some dementia), peripheral
vascular disease (causing limb ischemia, and some chronic kidney disease) and
venous thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United States.
According to the US National Institutes of Health ("NIH"), by 2030, the global
cost of CVD is set to rise to US$1,044 billion, from approximately US$863
billion in 2010, and is both a major health issue and global economic
burden.

 

GENinCode has a vision to assist clinicians and inform patients about
cardiovascular risk, and to improve public health using the predictive
capability of genomics. High genetic risk patients are assisted in making
lifestyle choices and can receive targeted treatment to improve outcomes. Over
the past 15 years, GENinCode has made a substantial investment in its
research, bioinformatic data, technology, and product development to assess
disease risk, in order to help clinicians and patients prevent the onset of
CVD.

 

Matthew Walls, CEO, GENinCode said: "We are delighted to work with the IU
School of Medicine and to introduce Cardio inCode-SCORE to the IU health
community. The IU study follows on from our recently published US clinical
performance studies showing the substantive predictive capability of the
Cardio inCode-SCORE product for the risk assessment of patients for the onset
of cardiovascular disease. We look forward to working closely with the IU team
to successfully deliver the programme."

 

Richard Kovacs MD, Q.E. and Sally Russell Professor of Cardiology in the
Division of Cardiovascular

Disease at IU School of Medicine commented: "The GENinCode and IU
collaboration offers the potential to improve the prediction of ASCVD and
better assess patient risk of future CVD events. GRS's provide an opportunity
to enhance assessment of risk based on 'classic' CVD risk factors and help
physicians identify patients at higher inherited genetic risk, thereby
targeting improved treatment and reduction in future CVD events. IU welcomes
this approach and we look forward to working with Cardio inCode-SCORE to
advance preventative CVD care."

 

For more information visit www.genincode.com (http://www.genincode.com)

 

 GENinCode Plc                              www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                      Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)       Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                        Tel: 020 7933 8780 or
 Anna Dunphy / Paul McManus / Louis Ashe-Jepson                               genincode@walbrookpr.com

 

About GENinCode:

 

GENinCode Plc is a UK based company specializing in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About Indiana University School of Medicine

IU School of Medicine is the largest medical school in the United States.
Comprised of five basic science departments and 20 clinical departments, IU
School of Medicine offers exceptional training for students wishing to pursue
a medical degree. With the Class of 2020, the school implemented a new medical
education curriculum that better reflects the modern U.S. health care
environment and delivery models, readying students to practice medicine in a
team-based, interdisciplinary setting.

·      Statewide medical education centers on six core competencies.

·      Access to diverse patient populations reflects true state of care
today.

·      Updates align innovations in medical science and education.

·      Global outreach, clinical education programs foster active
learning.

·      Collaborative teaching and learning forges interprofessional
bonds.

·      Academic advising and career counseling support and guide
students.

 

About Cardiovascular Disease (CVD or Heart Disease) in the US: Centres for
Disease Control Prevention information (CDC)

·      Heart disease is the leading cause of death for men, women,
and people of most racial and ethnic groups in the United States.

·      One person dies every 36 seconds in the United States from
cardiovascular disease.

·      About 659,000 people in the United States die from heart
disease each year-that's 1 in every 4 deaths.

·      Heart disease costs the United States about $363 billion each
year from 2016 to 2017.(2) This includes the cost of health care services,
medicines, and lost productivity due to death.

 

Coronary Artery Disease/Coronary Heart Disease

·      Coronary heart disease is the most common type of heart disease,
killing 360,900 people in 2019.

·      About 18.2 million adults age 20 and older have CAD (about
6.7%).

·      About 2 in 10 deaths from CAD happen in adults less than 65 years
old.

 

Heart Attack

·      In the United States, someone has a heart attack every 40
seconds.

·      Every year, about 805,000 people in the United States have a
heart attack.(  )Of these,

o  605,000 are a first heart attack

o  200,000 happen to people who have already had a heart attack

o  About 1 in 5 heart attacks is silent-the damage is done, but the person
is not aware of it.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJTMFTMTJTBLT